Generalized Pustular Psoriasis Market
DelveInsight’s Generalized Pustular Psoriasis (GPP) - Market
Insights, Epidemiology and Market Forecast-2028 report delivers
an in-depth understanding of the disease, historical & forecasted
epidemiology as well as the market trends of Generalized Pustular Psoriasis in
the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom),
and Japan.
The Report provides the current treatment practices, emerging drugs,
market share of the individual therapies, current and forecasted market size of
Generalized Pustular Psoriasis from 2017 to 2028 segmented by the seven major
markets. The Report also covers current treatment practice/algorithm, market
drivers, market barriers and unmet medical needs to curate best of the
opportunities and assess underlying potential of the market.
The United States
EU5 (Germany, France, Italy, Spain
and the United Kingdom)
Japan
Study Period: 2017-2028
Generalized Pustular Psoriasis (GPP) is a subtype of pustular psoriasis
characterized by painful and occasionally disfiguring cutaneous manifestations
with sepsis-like systemic symptoms.
GPP has been associated with abnormalities in the cytokine (messenger
protein) interleukin -36-receptor-antagonist signaling. This is due to
recessive IL36RN gene mutations systemic symptoms and systemic upset. GPP is
characterized by recurrent acute flares and these flares may result in: headache, rapid pulse rate, loss of appetite
and nausea and leg swelling.
The DelveInsight’s Generalized Pustular Psoriasis market report gives the
thorough understanding of the Generalized Pustular Psoriasis by including
details such as disease definition, classification, symptoms, etiology,
pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment
guidelines for GPP in the US, Europe, and Japan.
The GPP epidemiology division provide the insights about historical and
current patient pool and forecasted trend for every 7 major countries. It helps
to recognize the causes of current and forecasted trends by exploring numerous
studies and views of key opinion leaders. This part of the DelveInsight’s report
also provides the diagnosed patient pool and their trends along with
assumptions undertaken.
The disease epidemiology covered in the report provides historical as
well as forecasted epidemiology [segmented by Total Diagnosed Prevalence
Population, Gender Specific Diagnosed Prevalence Population, Age Specific
Diagnosed Prevalence Population and Severity Specific Diagnosed Prevalence
Population] scenario of Generalized Pustular Psoriasis in the 7MM covering the
United States, EU5 countries (Germany, France, Italy, Spain, and the United
Kingdom) and Japan from 2017-2028.
As per DelveInsight’s analysis, a higher percentage of diagnosed
prevalence was observed for females, in comparison to males. According to
DelveInsight, total diagnosed prevalent Population of GPP in the 7MM was
assessed to be more than 14,000 in 2017, which is expected to increase at a
CAGR of XX% for the study period i.e. 2017-2028.
Our estimates suggests highest diagnosed prevalence of GPP in the United
States with close to 6,000 cases in 2017. Furthermore, among the EU-5
countries, France had the highest diagnosed prevalent population of GPP,
followed by Germany and the United Kingdom. On the other hand, Spain was
assessed with the lowest diagnosed prevalent population. DelveInsight’s estimations
showed that Japan had 2,602 prevalent cases for GPP in 2017.
Assessments as per DelveInsight’s analysts showed that the severe cases
of GPP accounted for majority of the diagnosed prevalent population across 7MM
countries, followed by the number of patients with moderate symptoms. However,
the least number of cases were assessed for patient with mild symptoms.
This segment of the GPP report encloses the detailed analysis of marketed
drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to
understand the clinical trial details, expressive pharmacological action,
agreements and collaborations, approval and patent details, advantages and
disadvantages of each included drug and the latest news and press releases.
Tremfya (Guselkumab, CNTO1959) is a fully human anti-interleukin (IL)-23
HuCAL monoclonal antibody being marketed by Janssen for Generalized Pustular
Psoriasis in Japan. Guselkumab is a human monoclonal IgG1λ antibody that selectively
binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction
with the IL-23 receptor. Guselkumab is being developed by HuCAL antibody
library technology platform under a licensing agreement of Janssen
Pharmaceuticals with MorphoSys. Guselkumab is currently marketed in Japan for
the treatment of Generalized Pustular Psoriasis, pustular psoriasis, and
erythrodermic psoriasis in patients who have not responded sufficiently to
conventional therapies. However, it is not approved in the United States and
Europe for pustular psoriasis and erythrodermic psoriasis.
COSENTYX (Secukinumab) is a human IgG1 monoclonal antibody that
selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its
interaction with the IL-17 receptor. Secukinumab inhibits the release of
proinflammatory cytokines and chemokines. It is being marketed by Novartis
Pharmaceuticals for Generalized Pustular Psoriasis disease.
Lumicef (Brodalumab) is a human interleukin-17 receptor A (IL-17RA)
antagonist being marketed by Kyowa Hakko Kirin in Japan for Generalized
Pustular Psoriasis, pustular psoriasis, and erythrodermic psoriasis. It is a
human monoclonal IgG2 antibody that selectively binds to human IL-17RA and
inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F
heterodimer, and IL-25. In October 2010, Kyowa Hakko Kirin licensed from
Kirin-Amgen exclusive rights to develop and commercialize brodalumab in Japan
and certain other Asian countries.
Skyrizi (Risankizumab) is a humanized IgG1 monoclonal antibody that binds
to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role
in psoriatic inflammation. It is being marketed by Abbvie. Skyrizi is part of a
collaboration between BoehringerIngelheim and AbbVie, with AbbVie leading
development and commercialization of Skyrizi globally. Skyrizi is currently
under review with the U.S. Food and Drug Administration (FDA) and the company
expects a regulatory decision in the first half of 2019.
HUMIRA is a tumor necrosis factor (TNF) blocker being marketed by AbbVie/
Eisai for generalized pustular psoriasis and is available as a subcutaneous
Injection. In plaque psoriasis, treatment with HUMIRA may reduce the epidermal
thickness and infiltration of inflammatory cells.
Taltz (Ixekizumab) is a humanized IgG4 monoclonal antibody that
selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its
interaction with the IL-17 receptor and it inhibits the release of
proinflammatory cytokines and chemokines. It is being marketed by Eli Lilly
& company for Pustular Psoriasis in Japan.
REMICADE (Infliximab) is a tumor necrosis factor (TNF) blocker being
marketed by Mitsubishi Tanabe Pharma in Japan for Generalized Pustular
Psoriasis. It neutralizes the biological activity of TNFa by binding with high
affinity to the soluble and transmembrane forms of TNFa and inhibits binding of
TNFa with its receptors. In January 2010 REMICADE received the approval from
Ministry of Health, Labour and Welfare, Japan for additional indications
including pustular psoriasis, Erythrodermic Psoriasis.
The Generalized Pustular Psoriasis market outlook of the report helps to
build the detailed comprehension of the historic, current and forecasted trend
of the market by analyzing the impact of current therapies on the market, unmet
needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of market trend of each marketed
drug and late-stage pipeline therapy by evaluating their impact based on annual
cost of therapy, inclusion and exclusion criteria’s, mechanism of action,
compliance rate, growing need of the market, increasing patient pool, covered
patient segment, expected launch year, competition with other therapies, brand
value, their impact on the market and view of the key opinion leaders. The
calculated market data are presented with relevant tables and graphs to give a
clear view of the market at first sight.
The market size of GPP in the seven major markets is expected to grow at
a CAGR of 10.16% for the study period (2017-2028). The current therapeutic landscape
of GPP in the United States is driven by supportive therapies (topical
therapies, systemic therapies, biologics and phototherapy). In EU-5 countries,
for GPP, the market is same as that of the US, with prescriptions for
supportive therapies, due to lack of approved treatment regimens, and together
accounted for nearly USD 20.21 million in 2017. In contrast to the US and EU-5
countries, the current therapeutic landscape of GPP in Japan is driven by a
number of approved therapies, along with supportive treatment regimens.
A modest increase in market size of currently prescribed therapies has
been witnessed from 2017 until the launch of emerging therapies in respective
countries. The market share is expected to decline post that for current
therapies, across the 7MM, owing to the increasing demand for targeted
therapies to treat GPP. Among the current treatment regimens, biologics occupy
the highest number of prescriptions in the treatment market of GPP. Moreover,
combination therapies remain the mainstay in the treatment of GPP, irrespective
of the severity of the disease.
This section focusses on the rate of uptake of the potential drugs
recently launched in the market or will get launched in the market during the
study period from 2017-2028. The analysis covers market uptake by drugs;
patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons
behind the maximal use of new drugs and allows the comparison of the drugs on
the basis of market share and size which again will be useful in investigating
factors important in market uptake and in making financial and regulatory
decisions.
The dynamics of GPP market is anticipated to change in the coming years
owing to the expected launch of emerging therapies during the forecasted period
of 2019-2028. With this, several companies have shifted their focus toward this
therapeutic area, and two of the therapies are expected to enter the treatment
market of GPP during our forecast period, namely BI 655130
(BoehringerIngelheim) and ANB019 (AnaptysBio).
Spesolimab (BI655130) is a new biological entity and first-in-class,
intravenous, IL-36 receptor monoclonal antibody being in development for GPP
Psoriasis by BoehringerIngelheim. The drug candidate is the second compound
being developed under the company’s immunology division (after risankizumab)
and has already shown strong efficacy in early clinical testing with a single
dose in patients affected by GPP. The company intends to initiate a Phase III
study of BI655130 in Generalized Pustular Psoriasis from May 2019.
ANB019 is an interleukin-36-receptor inhibitor monoclonal antibody being
in Phase II stage of development by AnaptysBio for GPP. The drug candidate is
the company’s most advanced wholly-owned antibody programs which it initially
developing as a potentially first-in-class therapy for patients suffering from
GPP and palmoplantarpustulosis. AnaptysBio had already demonstrated favorable
safety, pharmacokinetics and pharmacodynamic properties of ANB019 in Phase I
clinical trial in healthy volunteers. The company has subsequently initiated a
10-patient open-label, multi-dose, single-arm Phase II trial of ANB019 in GPP
patients, also referred to as the GALLOP trial, where top-line data are
anticipated in mid-2019.
Generalized Pustular Psoriasis
Patient Population
Generalized Pustular Psoriasis
Therapeutic Approaches
Generalized Pustular Psoriasis
Pipeline Analysis
Generalized Pustular Psoriasis
Market Size and Generalized Pustular Psoriasis Market Trends
Generalized Pustular Psoriasis
Market Opportunities
Impact of upcoming Generalized
Pustular Psoriasis Therapies
10 Years Generalized Pustular
Psoriasis Forecast
Generalized Pustular Psoriasis 7MM
Coverage
Generalized Pustular Psoriasis
Epidemiology Segmentation
Key Cross Competition
Generalized Pustular Psoriasis
Market Size
Generalized Pustular Psoriasis
Drugs Uptake
Generalized Pustular Psoriasis
Pipeline Product Profiles
Generalized Pustular Psoriasis Key
Products and Generalized Pustular Psoriasis Key Players
Generalized Pustular Psoriasis
Market Drivers and Generalized Pustular Psoriasis Market Barriers
This DelveInsight report will help to develop Business Strategies by
understanding the trends shaping and driving Generalized Pustular Psoriasis
market
Organize sales and marketing efforts by identifying the best
opportunities for Generalized Pustular Psoriasis market
To understand the future market competition in the GPP market.
Comments
Post a Comment